Behrendt Dominik, Beltrame John, Hikiti Hiro, Wainstein Marco, Kinlay Scott, Selwyn Andrew P, Ganz Peter, Fang James C
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
J Heart Lung Transplant. 2006 Apr;25(4):426-33. doi: 10.1016/j.healun.2005.11.450.
Excessive vascular oxidant stress has been implicated in cardiac transplant-associated arteriosclerosis (TxAA). In a recent placebo-controlled study of 40 cardiac transplant recipients, vitamin C 500 mg twice a day and vitamin E 400 IU twice a day for 1 year retarded the progression of TxAA, as assessed by intravascular ultrasound (IVUS). Endothelial dysfunction is a key feature of TxAA and reflects oxidant stress. We hypothesized that coronary endothelial dysfunction portends greater TxAA progression and a larger therapeutic response to anti-oxidant vitamins.
In this pre-specified analysis, the 40 cardiac transplant recipients were categorized according to normal or abnormal coronary endothelial vasomotor function at baseline, as assessed by acetylcholine (10(-8) to 10(-6) mol/liter). The effect of anti-oxidant vitamins within these two groups of patients was assessed by the change in intimal index over 1 year using IVUS.
With placebo (n = 21), the increase in intimal index was greater in the presence vs absence of endothelial dysfunction (11 +/- 3% vs 5 +/- 1%, p < 0.05). Among patients with endothelial dysfunction (n = 21), the intimal index increased 11 +/- 3% with placebo, but decreased -1 +/- 2% with vitamins (p = 0.002). Among patients with normal endothelial function (n = 14), the intimal index increased 5 +/- 1% with placebo and 1 +/- 1% with vitamins (p < 0.05).
Endothelial dysfunction indicates rapid TxAA progression, even in the statin era. Although anti-oxidant vitamins reduce disease progression in patients with normal or abnormal endothelial function, the magnitude of benefit is larger in patients with endothelial dysfunction.
血管氧化应激过度与心脏移植相关动脉硬化(TxAA)有关。在最近一项针对40名心脏移植受者的安慰剂对照研究中,每天两次服用500毫克维生素C和每天两次服用400国际单位维生素E,持续1年,通过血管内超声(IVUS)评估,延缓了TxAA的进展。内皮功能障碍是TxAA的一个关键特征,反映了氧化应激。我们假设冠状动脉内皮功能障碍预示着TxAA进展更快,对抗氧化维生素的治疗反应更大。
在这项预先设定的分析中,根据基线时乙酰胆碱(10⁻⁸至10⁻⁶摩尔/升)评估的冠状动脉内皮血管运动功能正常或异常,将40名心脏移植受者进行分类。使用IVUS通过1年内内膜指数的变化评估这两组患者中抗氧化维生素的作用。
服用安慰剂(n = 21)时,存在内皮功能障碍组的内膜指数增加幅度大于无内皮功能障碍组(11±3%对5±1%,p < 0.05)。在内皮功能障碍患者(n = 21)中,服用安慰剂时内膜指数增加11±3%,而服用维生素时下降-1±2%(p = 0.002)。在内皮功能正常的患者(n = 14)中,服用安慰剂时内膜指数增加5±1%,服用维生素时增加1±1%(p < 0.05)。
内皮功能障碍表明即使在他汀类药物时代TxAA进展也很快。尽管抗氧化维生素可降低内皮功能正常或异常患者的疾病进展,但在内皮功能障碍患者中获益程度更大。